Current cigarette smoking is an independent risk factor for subacute stent thrombosis in acute myocardial infarction patients

Journal of Cardiology

Volumn 63, Issue 5, 2014, Pages 358-364

  Honda, Tsuyoshi ^a   Fujimoto, Kazuteru ^a   Miyao, Yuji ^a   Koga, Hidenobu ^a   Ishii, Masanobu ^a  

^a NATIONAL HOSPITAL ORGANIZATION KUMAMOTO MEDICAL CENTER   (Japan)

Author keywords

Acute myocardial infarction; Current smoker; Subacute stent thrombosis

Indexed keywords

CILOSTAZOL; CLOPIDOGREL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; JAPANESE (PEOPLE); LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTOR; SMOKING; STENT THROMBOSIS;

ACUTE MYOCARDIAL INFARCTION; CURRENT SMOKER; SUBACUTE STENT THROMBOSIS;

ACUTE DISEASE; AGE FACTORS; AGED; AGED, 80 AND OVER; CHOLESTEROL, LDL; FEMALE; FORECASTING; HEMOGLOBINS; HUMANS; INCIDENCE; LEUKOCYTE COUNT; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SMOKING; STENTS; STROKE VOLUME; THROMBOSIS; TRIGLYCERIDES;

EID: 84899933362     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2013.10.007     Document Type: Article

References (40)

1. Ockene I.S., Miller N.H. Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association (American Heart Association Task Force on Risk Reduction). Circulation 1997, 96:3243-3247.
2. Smith S.C, Milani R.V., Arnett D.K., Crouse J.R., McDermott M.M., Ridker P.M., Rosenson R.S., Taubert K.A., Wilson P.W. American Heart Association: Atherosclerotic Vascular Disease Conference: Writing Group II: Risk factors. Circulation 2004, 109:115-126.
3. Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., McQueen M., Budaj A., Varigos J., Lisheng L., INTERHEART Study Investigators Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
4. Kawano H., Soejima H., Kojima S., Kiyagawa A., Ogawa H., Japanese Acute Coronary Syndrome Study (JACSS) Investigators Sex differences of risk factors for acute myocardial infarction in Japanese patients. Circ J 2006, 70:513-517.
5. Yagi H., Komukai K., Hashimoto K., Kawai M., Ogawa T., Anzawa R., Minai K., Nagoshi T., Ogawa K., Taniguchi I., Yoshimura M. Difference in risk factors between acute coronary syndrome and stable angina pectoris in the Japanese: smoking as a crucial risk factor of acute coronary syndrome. J Cardiol 2010, 55:345-353.
6. Kelly T.L., Gilpin E., Ahnve S., Henning H., Ross J. Smoking status at the time of acute myocardial infarction and subsequent prognosis. Am Heart J 1985, 110:535-541.
7. Weisz G., Cox D.A., Garcia E., Tcheng J.E., Griffin J.J., Guagliumi G., Stuckey T.D., Rutherford B.D., Mehran R., Aymong E., Lansky A., Grines C.L., Stone G.W. Impact of smoking status on outcome of primary coronary intervention for acute myocardial infarction - the smoker's paradox revisited. Am Heart J 2005, 150:358-364.
8. Katayama T., Iwasaki Y., Sakoda N., Yoshioka M. The etiology of 'smoker's paradox' in acute myocardial infarction with special emphasis on the association with inflammation. Int Heart J 2008, 49:13-24.
9. Gerber Y., Rosen L.J., Goldbourt U., Benyamini Y., Drory Y., Israel Study Group on First Acute Myocardial Infarction Smoking status and long-term survival after first acute myocardial infarction a population-based cohort study. J Am Coll Cardiol 2009, 54:2282-2287.
10. Howe M., Leidal A., Montgomery D., Jackson E. Role of cigarette smoking and gender in acute coronary syndrome events. Am J Cardiol 2011, 108:1382-1386.
11. Beinart R., Abu Sham'a R., Segev A., Hod H., Guetta V., Shechter M., Boyko V., Behar S., Matetzky S. The incidence and clinical predictors of early stent thrombosis in patients with acute coronary syndrome. Am Heart J 2010, 159:118-124.
12. Ergelen M., Uyarel H., Osmonov D., Ayhan E., Akkaya E., Soylu O., Orhan A.L., Sayar N., Bozbay M., Turer A., Yildirim E., Yekeler I. Early stent thrombosis in patients undergoing primary coronary stenting for acute myocardial infarction: incidence, a simple risk score, and prognosis. Clin Appl Thromb Hemost 2010, 16:33-41.
13. Dangas G.D., Caxieta A., Mehran R., Parise H., Lansky A.J., Cristea E., Brodie B.R., Witzenbichler B., Guagliumi G., Peruga J.Z., Dudek D., Möeckel M., Stone G.W., Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial Investigators Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. Circulation 2011, 123:1745-1756.
14. Thygesen K., Alpert J.S., White H.D., Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction Universal definition of myocardial infarction. Circulation 2007, 116:2643-2653.
15. Brosius F.C., Hostertter T.H., Kelepouris E., Mitsnefes M.M., Moe S.M., Moore M.A., Pennathur S., Smith G.L., Wilson P.W., American Heart Association Kidney and Cardiovascular Disease Council, Council on High Blood Pressure Research, Council on Cardiovascular Disease in the Young, Council on Epidemiology and Prevention, Quality of Care and Outcomes Research Interdisciplinary Working Groups Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease. Circulation 2006, 114:1083-1087.
16. Honda T., Kanazawa H., Koga H., Miyao Y., Fujimoto K. Heart rate on admission is an independent risk factor for poor cardiac function and in-hospital death after acute myocardial infarction. J Cardiol 2010, 56:197-203.
17. Cutlip D.E., Windecker S., Mehran R., Boam A., Cohen D.J., van Es G.A., Steg P.G., Morel M.A., Mauri L., Vranckx P., McFadden E., Lansky A., Hamon M., Krucoff M.W., Serruys P.W., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007, 115:2344-2351.
18. Ishikawa T., Mutoh M., Fuda Y., Sakamoto H., Okada H., Higashitani M., Nakano Y., Yamaguchi J., Enta K., Satoh T., Imai K., Horie T., Mochizuki S. Documented subacute stent thrombosis within thirty days after stenting with sirolimus-eluting stent (Cypher) for acute myocardial infarction: a Japanese single center retrospective non-randomized study. Circ J 2006, 70:1091-1092.
19. Nagashima Z., Tsukahara K., Morita S., Endo T., Sugano T., Hibi K., Himeno H., Fukui K., Umemura S., Kimura K. Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes. J Cardiol 2013, 62:158-164.
20. Harmsze A.M., van Werkum J.W., Ten Berg J.M., Zwart B., Bouman H.J., Breet N.J., van't Hof A.W., Ruven H.J., Hackeng C.M., Klungel O.H., de Boer A., Deneer V.H. CYP2C19nd CYP2C9nd CYP2C9*3 alleles are associated 3 alleles are associated 2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. Eur Heart J 2010, 31:3046-3053.
21. Yasue H., Hirai N., Mizuno Y., Harada E., Itoh T., Yoshimura M., Kugiyama K., Ogawa H. Low-grade inflammation, thrombogenicity, and atherogenic lipid profile in cigarette smokers. Circ J 2006, 70:8-13.
22. Al-Bazi M.M., Elshal M.F., Khoja S.M. Reduced coenzyme Q10 in female smokers and its association with lipid profile in a young healthy adult population. Arch Med Sci 2011, 7:948-954.
23. Ridker P.M., Buring J.E., Cook N.R., Rifai N. C-related protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003, 107:391-397.
24. Dandona P., Aljada A., Chaudhuri A., Mohanty P., Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005, 111:1448-1454.
25. Malik S., Wong N.D., Franklin S., Pio J., Fairchild C., Chen R. Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein. Diabetes Care 2005, 28:690-693.
26. Kojima S., Sakamoto T., Ishihara M., Kimura K., Miyazaki S., Tei C., Hiraoka H., Sonoda M., Tsuchihashi K., Yamagishi M., Inoue T., Asada Y., Ikeda Y., Shirai M., Ogawa H., et al. The white blood cell count is an independent predictor of no-reflow and mortality following acute myocardial infarction in the coronary intervention era. Ann Med 2004, 36:153-160.
27. Honda T., Kaikita K., Tsujita K., Hayasaki T., Matsukawa M., Fuchigami S., Sugiyama S., Sakashita N., Ogawa H., Takeya M. Pioglitazone, peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders. J Mol Cell Cardiol 2008, 44:915-926.
28. Robinson K., Conroy R.M., Mulcahy R. Smoking and acute coronary heart disease: a comparative study. Br Heart J 1988, 60:465-469.
29. Hreybe H., Saba S. Location of acute myocardial infarction and associated arrhythmias and outcome. Clin Cardiol 2009, 32:274-277.
30. Shiraishi J., Kohno Y., Sawada T., Hashimoto S., Ito D., Kimura M., Matsui A., Yokoi H., Arihara M., Irie H., Hyogo M., Shima T., Nakamura T., Matoba S., Yamada H., et al. Prognostic impact of systolic blood pressure at admission on in-hospital outcome after percutaneous coronary intervention for acute myocardial infarction. J Cardiol 2012, 60:139-144.
31. Tsujita K., Nikolsky E., Lansky A.J., Dangas G., Fahy M., Brodie B.R., Dudek D., Möckel M., Ochala A., Mehran R., Stone G.W. Impact of anemia on clinical outcome of patients with ST-segment elevation myocardial infarction in relation to gender and adjunctive antithrombotic therapy (from the HORIZONS-AMI trial). Am J Cardiol 2010, 105:1385-1394.
32. Barron H.V., Cannon C.P., Murphy S.A., Braunwald E., Gibson C.M. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circulation 2000, 102:2329-2334.
33. King S.B. Optimizing antiplatelet therapy in coronary interventions. Clin Cardiol 2000, (Suppl 6):VI-8-VI-813.
34. Faxon D.P., Fuster V., Libby P., Beckman J.A., Hiatt W.R., Thompson R.W., Topper J.N., Annex B.H., Rundback J.H., Fabunmi R.P., Robertson R.M., Loscalzo J. American Heart Association: Atherosclerotic Vascular Disease Conference: Writing Group III: Pathophysiology. Circulation 2004, 109:2617-2625.
35. Ridker P.M., Brown N.J., Vaughan D.E., Harrison D.G., Mehta J.L. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004, 109:IV6-IV19.
36. Ferroni P., Basili S., Santilli F., Davì G. Low-density lipoprotein-lowering medication and platelet function. Pathophysiol Haemost Thromb 2006, 35:346-354.
37. Sposito A.C., Chapman M.J. Statin therapy in acute coronary syndromes mechanistic insight into clinical benefit. Atheroscler Thromb Vasc Biol 2002, 22:1524-1534.
38. Blum A., Shamburek R. The pleiotropic effects of statins on endothelial function and thrombogenesis. Atherosclerosis 2009, 203:325-330.
39. Wannamethee S.G., Lowe G.D., Shaper A.G., Rumley A., Lennon L., Whincup P.H. Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. Eur Heart J 2005, 26:1765-1773.
40. Caponnetto P., Russo C., Di Maria A., Morjaria J.B., Barton S., Guarino F., Basile E., Proiti M., Bertino G., Cacciola R.R., Polosa R. Circulating endothelial-coagulative activation markers after smoking cessation: a 12-month observational study. Eur J Clin Invest 2011, 41:616-626.